Filtros de búsqueda

Lista de obras de Marco Tagliamento

ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium

artículo científico publicado en 2020

Afatinib and Erlotinib in the treatment of squamous-cell lung cancer

artículo científico publicado en 2018

Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer

artículo científico publicado en 2019

Burning Questions in the Oncofertility Counseling of Young Breast Cancer Patients

scientific article published on 04 September 2020

CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine

artículo científico publicado en 2018

Call for ensuring cancer care continuity during COVID-19 pandemic

scientific article published on 01 May 2020

Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab

scientific article published on 01 October 2019

Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer

scientific article published on 29 June 2020

Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis

publication published on 26 October 2021

Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer

artículo científico publicado en 2017

Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak

artículo científico publicado en 2020

Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds

scientific article published on 07 June 2019

Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies

scientific article published on 02 September 2020

New emerging targets in cancer immunotherapy: the role of VISTA

scientific article published on 01 June 2020

Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus

artículo científico publicado en 2019

Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer

scientific article published in 2021

Oncological care organisation during COVID-19 outbreak

artículo científico publicado en 2020

Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient

scientific article published on 30 April 2020

RETRACTED ARTICLE: Can baseline endocrinological examination and thyroid ultrasound predict the development of thyroid disease in immunotherapy-treated patients? Results from a prospective, single-center, open-label study

artículo científico publicado en 2019

Radiomic detection of EGFR mutations in NSCLC

scientific article published on 04 November 2020

Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer.

artículo científico publicado en 2017

Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study

scientific article published on 20 July 2019

Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis.

artículo científico publicado en 2018

Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives

artículo científico publicado en 2020

The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer

article

The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients

artículo científico publicado en 2019

Update on the Management of Breast Cancer during Pregnancy

artículo científico publicado en 2020

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda